Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
Globe Newswire•05/08/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.